The ability of PDAP to generate droplets of a smaller aerodynamic size could offer advantages over currently marketed devices in terms of targeting IFN-γ to the distal airways for treatment of TB and/or IPF. Here, IFNG is linked to idiopathic pulmonary fibrosis.